TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Imcheck Therapeutics
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting

ImCheck Therapeutics presented promising clinical trial results for ICT01, a γ9δ2 T-cell activator, showing high remission rates and overall survival in older or unfit patients with newly diagnosed acute myeloid leukemia (AML) when combined with azacitidine and venetoclax.

Insights
IPSEY   neutral

Mentioned in context of a pending acquisition of ImCheck, with no specific performance details provided